
Congrès
Documents du congrès
Accéder aux résumés, posters et présentations présentés aux congrès suivants
Mars 2023
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
March 2023 (Atlanta, Georgia, USA)
Mars 2023
Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)
Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)
Mars 2023 (Paris, France)
Mars 2023
Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)
Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)
March 2023 (Fukuoka, Japan)
Février 2023
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )
February 2023 (Miami Beach, Florida, USA)
Posters
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib in patients with B-cell malignancies intolerant to acalabrutinib
Résumés
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients (pts) with B-cell malignancies who undergo treatment with zanubrutinib (zanu)
Zanubrutinib (zanu) in patients (pts) with B-cell malignancies intolerant to acalabrutinib (acala)
Février 2023
American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)
American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)
February 2023 (San Francisco, California, USA)
Février 2023
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)
February 2023 (Orlando, Florida, USA)
Janvier 2023
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
January 2023 (San Francisco, California, USA)
Présentations
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Posters
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Résumés
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Décembre 2022
American Society of Hematology (Société américaine d’hématologie) (ASH)
American Society of Hematology (Société américaine d’hématologie) (ASH)
December 2022 (New Orleans, Louisiana, USA)
Présentations
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free surivival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Posters
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relaped/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a nonrandomized, open-label, phase 1b/2 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Résumés
A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data
A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML)
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study
Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like?
Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Décembre 2022
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
Décembre 2022 (Genève, Suisse)
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced NSCLC
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer: RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer: RATIONALE-307 updated analysis
Résumés
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced non-small cell lung cancer
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer : RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer : RATIONALE-307 updated analysis
Décembre 2022
European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)
European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)
Décembre 2022 (Singapour)
Présentations
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy vs chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: the RATIONALE-301 Chinese subpopulation analysis
Résumés
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-302: tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): impact on health-related quality of life (HRQoL) in Asian patients
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 Chinese subpopulation analysis
Novembre 2022
Congrès allemand sur le cancer (DKK)
Congrès allemand sur le cancer (DKK)
Novembre 2022 (Berlin, Allemagne)
Novembre 2022
Association coréenne pour le cancer du poumon (Korean Association for Lung Cancer, KALC)
Association coréenne pour le cancer du poumon (Korean Association for Lung Cancer, KALC)
Novembre 2022 (Séoul, Corée du Sud)
Présentations
Novembre 2022
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
November 2022 (Boston, Massachusetts, USA)
Posters
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
Résumés
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
Novembre 2022
Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)
Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)
Novembre 2022 (Tróia, Portugal)
Résumés
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
Long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
Novembre 2022
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
Novembre 2022 (Vienne, Autriche)
Posters
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact analysis of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
Résumés
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
Novembre 2022
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Novembre 2022 (Chine)
Présentations
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
Posters
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for nonsquamous nsclc in patients aged 65-75 years
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (her2+) advanced/metastatic gastroesophageal adenocarcinoma
HERIZON-GEA-01: a phase 3 study of zanidatamabin combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Résumés
Time to response and depth of response in non-squamous non-small cell lung cancer patients treated with tislelizumab plus chemotherapy as first line therapy: an exploratory analysis of RATIONALE-304
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first line treatment for nonsquamous non-small cell lung cancer in patients aged 65-75 years
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
A matching-adjusted indirect comparison of tislelizumab versus camrelizumab as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-105: a phase 1 dose-verification study of ociperlimab in combination with tislelizumab in advanced solid tumors in Chinese patients
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Rationale-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer: sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Zanubrutinib plus obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Novembre 2022
Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)
Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)
Novembre 2022 (Brisbane, Australie)
Posters
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Résumés
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer
Octobre 2022
Atelier international sur la macroglobulinémie de Waldenström (International Workshop on Waldenström's Macroglobulinemia, IWWM)
Atelier international sur la macroglobulinémie de Waldenström (International Workshop on Waldenström's Macroglobulinemia, IWWM)
Octobre 2022 (Madrid, Espagne)
Présentations
ASPEN biomarker analysis: response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Extended follow-up of a phase 2 trial of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Zanubrutinib in patients intolerant to ibrutinib/acalabrutinib
Zanubrutinib or the treatment of patients with Waldenström macroglobulinemia: 4 years of follow-up
Résumés
ASPEN biomarker analysis: response to Bruton Tyrosine Kinase Inhibitor (BTKi) treatment in patients with Waldenström macroglobulinemia (WM) harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
Extended follow-up of a phase 2 trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Preliminary results for patients with Waldenström macroglobulinemia from the phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Octobre 2022
Société japonaise d’oncologie clinique (Japan Society of Clinical Oncology, JSCO)
Société japonaise d’oncologie clinique (Japan Society of Clinical Oncology, JSCO)
Octobre 2022 (Kobe, Japon)
Octobre 2022
Lymphome, leucémie et myélome (LLM)
Lymphome, leucémie et myélome (LLM)
October 2022 (New York, New York, USA)
Octobre 2022
Société japonaise d’hématologie (Japanese Society of Hematology, JSH)
Société japonaise d’hématologie (Japanese Society of Hematology, JSH)
Octobre 2022 (Fukuoka, Japon)
Octobre 2022
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)
Octobre 2022 (Vienne, Autriche)
Présentations
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Posters
Randomized, phase 3 study of second-line treatment vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Résumés
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQOL)
Octobre 2022
Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)
Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)
Octobre 2022 (Barcelone, Espagne)
Présentations
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (Bcl-2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve CLL/SLL
Posters
Résumés
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
Septembre 2022
Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)
Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)
September 2022 (Houston, Texas, USA)
Posters
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs. ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Résumés
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septembre 2022
Italian Society of Hematology (Société italienne d’hématologie) (SIE)
Italian Society of Hematology (Société italienne d’hématologie) (SIE)
Septembre 2022 (Rome, Italie)
Présentations
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma: subgroup analysis of the MAGNOLIA study
Zanubrutinib plus obtinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Posters
A phase 2 study with the novel B-cell lymphoma (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Résumés
A phase 2 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients (pts) with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib (zanu) in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Septembre 2022
Société néo-zélandaise d’oncologie (New Zealand Society for Oncology, NZSO)
Société néo-zélandaise d’oncologie (New Zealand Society for Oncology, NZSO)
Septembre 2022 (Christchurch, Nouvelle-Zélande)
Septembre 2022
Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]
Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]
Septembre 2022 (Sydney, Australie)
Présentations
A phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with AML
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Posters
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
Population-wide patterns of care in CLL in Australia: an analysis of the pharmaceutical benefits scheme data set
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme data set
Résumés
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Population-wide patterns of care in chronic lymphocytic leukemia (CLL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Population-wide patterns of care in mantle cell lymphoma (MCL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septembre 2022
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
Septembre 2022 (Paris, France)
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab + tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvanTIG-205: phase 2 trial of ociperlimab plus tislelizumab plus chemotherapy in first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer
DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
SAFFRON-301: a phase 3 study of tislelizumab with sitravatinib versus chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer previously treated with platinum-based chemotherapy and an anti-PD-1/PD-L1 antibody
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with advanced non-small cell lung cancer (NSCLC): Asian and non-Asian subgroup analysis of the RATIONALE-303 study
Résumés
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
AdvanTIG-205: phase 2 trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
Final analysis of RATIONALE-301: randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Phase 3 study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody
Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study
Septembre 2022
Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)
Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)
Septembre 2022 (Bydgoszcz, Pologne)
Présentations
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Résumés
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septembre 2022
Korean Society of Medical Oncology (KSMO)
Korean Society of Medical Oncology (KSMO)
Septembre 2022 (Séoul, Corée du Sud)
Présentations
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Résumés
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
HERIZON-GEA-01: phase 3 study of zanidatamab (ZANI) + chemotherapy (chemo) ± tislelizumab (TIS) in first-line (1L) human epidermal growth factor receptor 2 positive (HER2+) locally advanced (LA)/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Août 2022
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
Août 2022 (Vienne, Autriche)
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer (NSCLC): final analysis of RATIONALE-303
Résumés
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, non-squamous NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Juillet 2022
Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)
Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)
Juillet 2022 (Kauai, Hawaï)
Posters
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in 13 acalabrutinib‑intolerant patients with B‑Cell malignancies
Résumés
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib (ZANU) versus bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in 13 acalabrutinib‑intolerant patients (pts) with B‑cell malignancies
Juin 2022
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
Juin 2022 (Barcelone, Espagne)
Posters
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma: RATIONALE-208 Chinese subpopulation
Résumés
RATIONALE-306: randomized, multi-regional, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
Juin 2022
Asian Oncology Society (Société asiatique d'oncologie) (AOS)
Asian Oncology Society (Société asiatique d'oncologie) (AOS)
Juin 2022 (Séoul, Corée du Sud)
Juin 2022
European Hematology Association (Association européenne d’hématologie) (EHA)
European Hematology Association (Association européenne d’hématologie) (EHA)
Juin 2022 (Vienne, Autriche)
Posters
A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress)
A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set
Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study
Résumés
A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress)
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Juin 2022
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
June 2022 (Chicago, Illinois, USA)
Présentations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
RATIONALE-309: updated PFS, PFS2, and OS from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer
Posters
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Résumés
A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM)
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup
Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL)
Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL)
Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Mai 2022
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
Avril 2022 (Washington, DC, États-Unis)
Mai 2022
International Conference on Clinical and Experimental Hematology (Conférence internationale sur l'hématologie clinique et expérimentale) (ICCEH)
International Conference on Clinical and Experimental Hematology (Conférence internationale sur l'hématologie clinique et expérimentale) (ICCEH)
Mai 2022 (Lublin, Pologne)
Avril 2022
Transplantation & Cellular Therapy (Greffe et thérapie cellulaire) (TCT)
Transplantation & Cellular Therapy (Greffe et thérapie cellulaire) (TCT)
April 2022 (Salt Lake City, Utah, USA)
Avril 2022
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO) Plenary Series Program
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO) Plenary Series Program
Avril 2022 (virtuel)
Avril 2022
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
April 2022 (New Orleans, Louisiana, USA)
Posters
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
Co-enrichment of CD8 T-cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for non-squamous NSCLC in patients aged 65-75 years
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer
The combination of hyperamplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab versus docetaxel in patients with previously treated advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous (sq) non-small cell lung cancer (NSCLC): subanalysis from phase 3 RATIONALE-303 randomized clinical study
Résumés
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
CD8 T cells and macrophage abundances associated with clinical benefit of tislelizumab in various tumor types
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65–75 years
RATIONALE-304: the association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced non-squamous (non-sq) non-small-cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Avril 2022
British Society for Haematology (Société britannique d’hématologie) (BSH)
British Society for Haematology (Société britannique d’hématologie) (BSH)
Avril 2022 (Manchester, Royaume-Uni)
Posters
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Résumés
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
MARS 2022
Italian Society of Experimental Hematology (Société italienne d’hématologie expérimentale) (SIES)
Italian Society of Experimental Hematology (Société italienne d’hématologie expérimentale) (SIES)
Mars 2022 (Rome, Italie)
MARS 2022
Korean Society of Hematology (Société coréenne d'hématologie) (KSH)
Korean Society of Hematology (Société coréenne d'hématologie) (KSH)
Mars 2022 (Séoul, Corée du Sud)
MARS 2022
European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)
European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)
Mars 2022 (virtuel)
Posters
AdvanTIG-204: anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab plus concurrent chemoradiotherapy in patients with untreated limited-stage small cell lung cancer
RATIONALE-307: safety analysis of patients receiving tislelizumab plus chemotherapy versus chemotherapy alone in advanced squamous NSCLC
Résumés
AdvanTIG-204: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
RATIONALE-307: safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC
MARS 2022
French Society of Hematology (Société française d’hématologie) (SFH)
French Society of Hematology (Société française d’hématologie) (SFH)
Mars 2022 (Paris, France)
MARS 2022
Society of Gynecologic Oncology (Société d’oncologie gynécologique) (SGO)
Society of Gynecologic Oncology (Société d’oncologie gynécologique) (SGO)
Mars 2022 (Phoenix, Arizona, États-Unis)
Posters
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously-treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
Résumés
AdvanTIG-202: a phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
MARS 2022
Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)
Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)
Mars 2022 (Paris, France)
MARS 2022
European Society of Medical Oncology Targeted Anticancer Therapies (Société européenne d’oncologie médicale, thérapies anticancéreuses ciblées) (ESMO-TAT)
European Society of Medical Oncology Targeted Anticancer Therapies (Société européenne d’oncologie médicale, thérapies anticancéreuses ciblées) (ESMO-TAT)
Mars 2022 (virtuel)
Posters
Février 2022
Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)
Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)
Février 2022 (Kyoto, Japon)
Janvier 2022
British Thoracic Oncology Group (groupe d’oncologie thoracique britannique) (BTOG)
British Thoracic Oncology Group (groupe d’oncologie thoracique britannique) (BTOG)
Janvier 2022 (virtuel)
Janvier 2022
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
January 2022 (San Francisco, California, USA)
Posters
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors
Résumés
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Décembre 2021
American Society of Hematology (Société américaine d’hématologie) (ASH)
American Society of Hematology (Société américaine d’hématologie) (ASH)
Décembre 2021 (Atlanta, Géorgie, États-Unis)
Présentations
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in combination with venetoclax for patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Posters
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK-inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
Résumés
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Décembre 2021
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
Décembre 2021 (Genève, Suisse)
Posters
AdvanTIG-301: anti-TIGIT monoclonal antibody ociperlimab + tislelizumab + concurrent chemoradiotherapy followed by ociperlimab + tislelizumab or tislelizumab + concurrent chemoradiotherapy followed by tislelizumab versus concurrent chemoradiotherapy followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer
Résumés
AdvanTIG-301: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC
RATIONALE 309: a randomized, global, double-blind, phase 3 trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as 1L treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Décembre 2021
Immunotherapy Bridge (IBC)
Immunotherapy Bridge (IBC)
Décembre 2021 (virtuel)
Novembre 2021
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
Novembre 2021 (virtuel)
Posters
Novembre 2021
Australasian Melanoma Conference (Conférence australasienne sur le mélanome) (AMC)
Australasian Melanoma Conference (Conférence australasienne sur le mélanome) (AMC)
Novembre 2021 (Sydney, Australie)
Novembre 2021
Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)
Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)
Novembre 2021 (Melbourne, Australie)
Novembre 2021
Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)
Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)
Novembre 2021 (Espinho, Portugal)
Présentations
Novembre 2021
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
November 2021 (Washington, DC, USA)
Posters
Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
Association of tumor mutation burden and genomic alterations with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab
Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Résumés
Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab
Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Octobre 2021
Italian Society of Hematology (Société italienne d’hématologie) (SIE)
Italian Society of Hematology (Société italienne d’hématologie) (SIE)
Octobre 2021 (Milan, Italie)
Présentations
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM)
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenstrӧm macroglobulinemia (WM)
Octobre 2021
Academy of Managed Care Pharmacy Nexus (Nexus Académie de gestion pharmaceutique des soins) (AMCP Nexus)
Academy of Managed Care Pharmacy Nexus (Nexus Académie de gestion pharmaceutique des soins) (AMCP Nexus)
Octobre 2021 (Denver, Colorado, États-Unis)
Posters
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia in the United States
Real-world treatment pattern, adherence, cost and healthcare resource utilization of commercially-insured patients with Waldenstrӧm macroglobulinemia in the United States
Zanubrutinib versus ibrutinib to treat adult patients with Waldenstrӧm macroglobulinemia: a cost per response model from a payer perspective in the United States
Résumés
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia in the United States
Real-world treatment pattern, adherence, cost and healthcare resource utilization of commercially-insured patients with Waldenstrӧm macroglobulinemia in the United States
Zanubrutinib versus ibrutinib to treat adult patients with Waldenstrӧm macroglobulinemia: a cost per response model from a payer perspective in the United States
Octobre 2021
Spanish Society of Medical Oncology (Société espagnole d’oncologie médicale) (SEOM)
Spanish Society of Medical Oncology (Société espagnole d’oncologie médicale) (SEOM)
Octobre 2021 (virtuel)
Octobre 2021
Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)
Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)
Octobre 2021 (Pampelune, Espagne)
Posters
Octobre 2021
Australasian Gastro-Intestinal Trials Group (Groupe australasien d’essais gastro-intestinaux) (AGITG)
Australasian Gastro-Intestinal Trials Group (Groupe australasien d’essais gastro-intestinaux) (AGITG)
Octobre 2021 (virtuel)
Posters
ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
Résumés
AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
Octobre 2021
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)
Octobre 2021 (Berlin, Allemagne)
Présentations
Septembre 2021
Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)
Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)
Septembre 2021 (Rome, Italie)
Posters
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrӧm macroglobulinemia
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenstrӧm macroglobulinemia
Septembre 2021
Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]
Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]
Septembre 2021 (virtuel)
Septembre 2021
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
Septembre 2021 (virtuel)
Posters
Association between use of antibiotics and clinical outcomes with tislelizumab monotherapy
DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Effects of tislelizumab monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma
RATIONALE 304: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for non-squamous non-small cell lung cancer in patients who are smokers vs non-smokers
RATIONALE 307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer in patients who were smokers versus non-smokers
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer
Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer
Résumés
Association between use of antibiotics (ATB) and clinical outcomes with tislelizumab (tisle) monotherapy
DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
RATIONALE 304: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first‑line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers
RATIONALE 307: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
Septembre 2021
International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)
International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)
Septembre 2021 (virtuel)
Posters
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia (CLL) in the United States
Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Résumés
A real-world study to assess the association of cardiovascular adverse events with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septembre 2021
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Septembre 2021 (virtuel)
Présentations
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years
Results from RATIONALE-303: a global phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Résumés
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years
Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septembre 2021
French Society of Hematology (Société française d’hématologie) (SFH)
French Society of Hematology (Société française d’hématologie) (SFH)
Septembre 2021 (Paris, France)
Présentations
Posters
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenström macroglobulinemia (MYD88WT WM)
Septembre 2021
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
Septembre 2021 (virtuel)
Posters
RATIONALE 307: a subgroup analysis of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for Stage IIIB advanced squamous NSCLC
RATIONALE-303 phase 3 tislelizumab vs docetaxel in previously treated advanced NSCLC: China subgroup analysis
RATIONALE-307: updated biomarker analysis of phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone for 1L advanced sq-NSCLC
Résumés
RATIONALE 307: a subgroup analysis of tislelizumab plus chemo vs chemo alone as 1L treatment for Stage IIIB advanced sq NSCLC
RATIONALE-303 phase 3 tislelizumab vs docetaxel in previously treated advanced NSCLC: China subgroup analysis
RATIONALE-307: updated biomarker analysis of phase 3 study of tislelizumab plus chemo vs chemo alone for 1L advanced sq-NSCLC
Septembre 2021
Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)
Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)
Septembre 2021 (virtuel)
Août 2021
Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)
Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)
Août 2021 (Big Island, Hawaii)
Juillet 2021
International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)
International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)
Juillet 2021 (Séoul, Corée du Sud)
Juin 2021
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
Juin 2021 (virtuel)
Présentations
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and the Europe/North America subgroup
Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma
Résumés
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
Juin 2021
International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)
International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)
Juin 2021 (virtuel)
Posters
Résumés
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Juin 2021
European Hematology Association (Association européenne d’hématologie) (EHA)
European Hematology Association (Association européenne d’hématologie) (EHA)
Juin 2021 (virtuel)
Présentations
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Posters
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of a phase 2 study of zanubrutinib in patients with previously treated B cell malignancies intolerant to ibrutinib/acalabrutinib
Preliminary safety data from patients with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Résumés
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrӧm macroglobulinemia: matching-adjusted indirect comparisons
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a phase 2 study
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Juin 2021
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
Juin 2021 (virtuel)
Posters
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-302: anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer
Efficacy and safety of zanubrutinib versus rituximab-based chemotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons
PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65
The effects of tislelizumab treatment on the health-related quality of life of non−small cell lung cancer patients who progressed on a prior platinum-containing regimen
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
Résumés
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) vs pembrolizumab (PEM) in programmed death ligand 1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC)
Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States